
Teva spared payout to GSK over patent infringement dispute
pharmafile | March 29, 2018 | News story | Sales and Marketing | Coreg, GSK, GlaxoSmithKline, Teva, carvedilol, heart failure, pharma
Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that the Israeli firm hand over $235 million in damages related to infringement of one of the latter’s patents.
The original ruling, made in June last year, judged that Teva had caused doctors to breach GSK’s patent on its blood pressure therapy Coreg through sales of the generic version carvedilol as a substitute in the treatment of chronic heart failure. This resulted in $234.1 million in lost profits, which Teva was required to pay, plus $1.4 million in royalties.
US District Judge Leonard Stark made the new ruling, asserting that evidence did not support the view that Teva was responsible for the infringement of the patent in question over other factors.
“Without proof of causation, which is an essential element of GSK’s action, a finding of inducement cannot stand,” he said.
Judge Stark did not however overturn the earlier decision to reject Teva’s view that the patent was invalid.
Unsurprisingly, GSK were not happy with the ruling: “We are disappointed with the judge’s decision and are reviewing our options,” the company said in a statement.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …





